Patents by Inventor Stephen P. Mayfield

Stephen P. Mayfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11578335
    Abstract: This invention provides synthetic promoters capable of promoting and/or initiating transcription of a polynucleotide in an algal cell, and methods of designing, producing and using such promoters.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: February 14, 2023
    Assignee: The Regents of the University of California
    Inventors: Stephen P. Mayfield, Melissa Scranton, David Ryan Georgianna, Joseph Ostrand, Anthony Jason Erich Berndt
  • Publication number: 20190382779
    Abstract: This invention provides synthetic promoters capable of promoting and/or initiating transcription of a polynucleotide in an algal cell, and methods of designing, producing and using such promoters.
    Type: Application
    Filed: February 16, 2017
    Publication date: December 19, 2019
    Applicant: The Regents of the University of California
    Inventors: Stephen P. MAYFIELD, Melissa SCRANTON, David Ryan GEORGIANNA, Joseph OSTRAND, Anthony Jason Erich BERNDT
  • Patent number: 10047371
    Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: August 14, 2018
    Assignee: The Regents of the University of California
    Inventors: Stephen P. Mayfield, Beth A. Rasala, Miller Tran
  • Publication number: 20170342434
    Abstract: Provided are chloroplasts engineered to recombinantly express mammalian colostrum and milk polypeptides photosynthetic organisms containing such chloroplasts, and compositions comprising such organisms and methods for producing such organisms. In certain embodiments, provided is a chloroplast comprising one or more polynucleotides encoding one or more mammalian milk or colostrum polypeptides selected from osteopontin, lactadherin, cathelicidin-1, lysozyme, lactoperoxidase, lingual antimicrobial peptide (LAP), alpha-lactalbumin, and soluble CD14.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Applicant: The Regents of the University of California
    Inventors: Stephen P. MAYFIELD, Austin HALLGREN, Beth A. RASALA, Miller TRAN, Michael MAYFIELD
  • Patent number: 9732351
    Abstract: Provided are chloroplasts engineered to recombinantly express mammalian colostrum and milk polypeptides, photosynthetic organisms containing such chloroplasts, and compositions comprising such organisms and methods for producing such organisms. In certain embodiments, provided is a chloroplast comprising one or more polynucleotides encoding one or more mammalian milk or colostrum polypeptides selected from osteopontin, lactadherin, cathelicidin-1, lysozyme, lactoperoxidase, lingual antimicrobial peptide (LAP), alpha-lactalbumin, and soluble CD14.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 15, 2017
    Assignee: The Regents of the University of California
    Inventors: Stephen P. Mayfield, Austin Hallgren, Beth A. Rasala, Miller Tran, Michael Mayfield
  • Publication number: 20170015745
    Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents.
    Type: Application
    Filed: July 5, 2016
    Publication date: January 19, 2017
    Inventors: Stephen P. Mayfield, Miller Tran
  • Publication number: 20170009250
    Abstract: The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFN?), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 12, 2017
    Applicants: Sapphire Energy, Inc., The Scripps Research Institute
    Inventors: Beth A. Rasala, Rosa M. F. Cardoso, Machiko Muto, Stephen P. Mayfield, Philip A. Lee, Craig A. Behnke, Michael Mendez
  • Publication number: 20160369291
    Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.
    Type: Application
    Filed: February 19, 2015
    Publication date: December 22, 2016
    Applicant: The Regents of the University of California
    Inventors: Stephen P. MAYFIELD, Beth A. RASALA, Miller TRAN
  • Publication number: 20160257730
    Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.
    Type: Application
    Filed: April 22, 2016
    Publication date: September 8, 2016
    Applicant: The Regents of the University of California
    Inventors: Stephen P. MAYFIELD, Austin HALLGREN, Beth A. RASALA, Miller TRAN, Michael MAYFIELD
  • Patent number: 9422347
    Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: August 23, 2016
    Assignee: The Regents of the University of California
    Inventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
  • Patent number: 8932576
    Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: January 13, 2015
    Assignee: The Scripps Research Institute
    Inventor: Stephen P. Mayfield
  • Publication number: 20140219971
    Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.
    Type: Application
    Filed: May 1, 2012
    Publication date: August 7, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
  • Publication number: 20120309939
    Abstract: The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFN?), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.
    Type: Application
    Filed: November 19, 2010
    Publication date: December 6, 2012
    Applicants: THE SCRIPPS RESEARCH INSTITUTE, SAPPHIRE ENERGY, INC.
    Inventors: Beth A. Rasala, Rosa M. F. Cardoso, Machiko Muto, Stephen P. Mayfield, Philip A. Lee, Craig A. Behnke, Michael Mendez
  • Publication number: 20100129394
    Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed.
    Type: Application
    Filed: January 27, 2010
    Publication date: May 27, 2010
    Inventor: Stephen P. Mayfield
  • Patent number: 7678561
    Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery or proteins/peptides, especially gut active proteins, without purification is disclosed.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: March 16, 2010
    Assignee: The Scripps Research Institute
    Inventor: Stephen P. Mayfield
  • Publication number: 20090148904
    Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents.
    Type: Application
    Filed: November 12, 2008
    Publication date: June 11, 2009
    Inventor: Stephen P. Mayfield
  • Publication number: 20040014174
    Abstract: Methods of producing one or more polypeptides in a plant chloroplast, including methods of producing polypeptides that specifically associate in a plant chloroplast to generate a functional protein complex, are provided. An isolated polynucleotide that includes (or encodes) a first ribosome binding sequence (RBS) operatively linked to a second RBS, such that the first RBS directs translation of a polypeptide in a prokaryote and the second RBS directs translation of the polypeptide in a chloroplast, also is provided, as is a vector containing such a polynucleotide, particularly a chloroplast vector and a chloroplast/prokaryote shuttle vector. Also provided is a synthetic polynucleotide, which is chloroplast codon biased. A plant cell that is genetically modified to contain a polynucleotide or vector as described above, as well as transgenic plants containing or derived from such a genetically modified cell, are provide. Polypeptides encoded by a synthetic polynucleotide as described also are provided.
    Type: Application
    Filed: April 23, 2003
    Publication date: January 22, 2004
    Inventors: Stephen P. Mayfield, Scott Franklin
  • Patent number: RE39350
    Abstract: The present invention relates to a gene expression system in eukaryotic and prokaryotic cells, preferably plant cells and intact plants. In particular, the invention relates to an expression system having a RB47 binding site upstream of a translation initiation site for regulation of translation mediated by binding of RB47 protein, a member of the poly(A) binding protein family. Regulation is further effected by RB60, a protein disulfide isomerase. The expression system is capable of functioning in the nuclear/cytoplasm of cells and in the chloroplast of plants. Translation regulation of a desired molecule is enhanced approximately 100 fold over that obtained without RB47 binding site activation.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: October 17, 2006
    Assignee: The Scripps Research Institute
    Inventor: Stephen P. Mayfield
  • Patent number: RE44266
    Abstract: The present invention relates to a gene expression system in eukaryotic and prokaryotic cells, preferably plant cells and intact plants. In particular, the invention relates to an expression system having a RB47 binding site upstream of a translation initiation site for regulation of translation mediated by binding of RB47 protein, a member of the poly(A) binding protein family. Regulation is further effected by RB60, a protein disulfide isomerase. The expression system is capable of functioning in the nuclear/cytoplasm of cells and in the chloroplast of plants. Translation regulation of a desired molecule is enhanced approximately 100 fold over that obtained without RB47 binding site activation.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: June 4, 2013
    Assignee: The Scripps Research Institute
    Inventor: Stephen P. Mayfield